CutisPharma adds drug manufacturing to its operations

CutisPharma, a specialty pharma company with a background in selling kits used by retail pharmacies to compounded medications, has now gotten into the manufacturing side of things itself. The company kicked off new manufacturing operations at its Wilmington, MA, headquarters on Wednesday. A spokesman said CutisPharma invested $4 million in the FDA GMP-compliant facility and is in the process of hiring. It has already added 15 people, bringing its total to 50, and expects to add up to 100 more as its moves for FDA approval of applications for generic drugs. It has worked with contract manufacturers in the past, the spokesman said. Release

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.